GlassScriptPhysician profile
Max Frederick Bergstrom
NPI 1104591874
$2,606.65
in general payments reported to CMS, 2019-2025
47 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $331 · 2023: $1,316 · 2024: $667 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.65 |
| Education | $188.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $234.77 | 2023-2025 | Verzenio, Jaypirca, Mounjaro |
| Abbvie INC. | $181.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.81 | 2023-2025 | Airsupra, Imfinzi, Calquence |
| Amgen INC. | $160.78 | 2023-2025 | Evenity, Prolia, Otezla |
| Bioventus LLC | $155.57 | 2022-2023 | Exogen Ultrasound Bone Healing System |
| Janssen Biotech, INC. | $153.80 | 2023-2024 | Darzalex, Imbruvica, Tecvayli |
| Integra Lifesciences Corporation | $90.91 | 2022 | |
| Incyte Corporation | $89.43 | 2023-2024 | Jakafi, Monjuvi |
| Heron Therapeutics, INC. | $86.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $81.39 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $67.76 | 2023-2024 | Keytruda, Welireg |
| Novo Nordisk INC | $67.37 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $64.66 | 2023-2024 | |
| Sonex Health, INC. | $63.48 | 2023 | Sx-One Microknife |
| Daiichi Sankyo INC. | $59.53 | 2023-2024 | Enhertu, Injectafer |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $56.30 | 2023 | Tukysa, Padcev |
| Endo Pharmaceuticals INC. | $49.20 | 2022-2023 | Xiaflex |
| Emd Serono, INC. | $46.44 | 2023-2024 | Bavencio |
| Genentech USA, INC. | $46.12 | 2023 | Lunsumio, Polivy, Columvi |
| Exelixis INC. | $42.40 | 2023 | Cabometyx |
| Jazz Pharmaceuticals INC. | $36.24 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $35.16 | 2023 | Eliquis, Opdivo |
| Deciphera Pharmaceuticals INC. | $34.90 | 2023 | Qinlock |
| Glaxosmithkline, LLC. | $33.02 | 2023-2024 | Ojjaara, Shingrix |
| Aveo Pharmaceuticals, INC. | $32.52 | 2023 | Fotivda |
| Corium, LLC | $29.55 | 2024 | Azstarys |
| Mylan Institutional INC. | $28.36 | 2023 | Fulphila, Ogivri |
| Tempus Ai, INC | $27.65 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.41 | 2024 | Alunbrig |
| Karyopharm Therapeutics INC. | $27.33 | 2023 | Xpovio |
| Servier Pharmaceuticals LLC | $24.77 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $24.33 | 2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $23.69 | 2023 | Libtayo |
| Immunogen, INC. | $21.95 | 2024 | Elahere |
| Janssen Pharmaceuticals, INC | $21.25 | 2023 | Xarelto |
| Morphosys, US INC. | $20.17 | 2023 | Monjuvi |
| Accord Healthcare, INC. | $19.22 | 2023 | |
| Rigel Pharmaceuticals, INC. | $18.91 | 2023 | Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.71 | 2023 | Gilotrif |
| Array Biopharma INC | $18.35 | 2023 | Braftovi, Lorbrena, Mektovi |
| Genmab U.S., INC. | $16.47 | 2024 | Epkinly |
| G1 Therapeutics, INC. | $15.73 | 2023 | Cosela |
| Cumberland Pharmaceuticals, INC. | $15.40 | 2023 | Sancuso |
| Astellas Pharma US INC | $15.03 | 2024 | Padcev |
| Exact Sciences Corporation | $15.03 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $14.77 | 2024 | |
| Phathom Pharmaceuticals, INC. | $13.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Bergstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.